# Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC

Source: https://onco.cc/trials/nct07405190/  
OnCo record `nct07405190` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of ivonescimab, carboplatin and pemetrexed in lung cancer, run by Massachusetts General Hospital, now recruiting.

## Summary

Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC is a phase 2, interventional study registered as NCT07405190 by Massachusetts General Hospital, with a registry enrolment figure of 46 participants, started 2026-05-01 and due to reach its primary completion in 2028-03-01. Interventions recorded: Ivonescimab; carboplatin; pemetrexed. Conditions listed: Lung Cancer (NSCLC); Lung Cancer Non-Small Cell Cancer (NSCLC); Lung Cancer (Non-Small Cell); Lung Cancer - Non Small Cell; Lung Cancer Non Small Cell; Genomic Alterations. Primary outcome: Objective Response Rate (ORR) of Ivonescimab Monotherapy; Objective Response Rate (ORR) of Ivonescimab plus Carboplatin/Pemetrexed. Lung eligibility wording from the registry: "* Histologically or cytologically confirmed advanced or metastatic non-squamous NSCLC not amenable to curative resection or radiation". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07405190
- Phase: 2
- Setting: A Phase II Study of Ivonescimab as Monotherapy or in Combination With Platinum/Pemetrexed Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring Actionable Genomic Alterations (AGAs)
- Sponsor: Massachusetts General Hospital
- Enrolled: 46

## Sources

- ClinicalTrials.gov NCT07405190: https://clinicaltrials.gov/study/NCT07405190

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Summit Therapeutics](https://onco.cc/companies/summit-therapeutics/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07405190.json